SUMMARY: From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.
SUMMARY: From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.
Authors: Peiqi Chen; Julie H Satterwhite; Angelo A Licata; E Michael Lewiecki; Adrien A Sipos; Derek M Misurski; Rachel B Wagman Journal: J Bone Miner Res Date: 2005-01-18 Impact factor: 6.741
Authors: Somnath Sarkar; Bruce H Mitlak; Mayme Wong; John L Stock; Dennis M Black; Kristine D Harper Journal: J Bone Miner Res Date: 2002-01 Impact factor: 6.741
Authors: Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: S Vasikaran; R Eastell; O Bruyère; A J Foldes; P Garnero; A Griesmacher; M McClung; H A Morris; S Silverman; T Trenti; D A Wahl; C Cooper; J A Kanis Journal: Osteoporos Int Date: 2010-12-24 Impact factor: 4.507
Authors: P Farahmand; F Marin; F Hawkins; R Möricke; J D Ringe; C-C Glüer; N Papaioannou; S Minisola; G Martínez; J M Nolla; C Niedhart; N Guañabens; R Nuti; E Martín-Mola; F Thomasius; J Peña; C Graeff; G Kapetanos; H Petto; A Gentzel; A Reisinger; P K Zysset Journal: Osteoporos Int Date: 2013-06-06 Impact factor: 4.507